General Information of Drug (ID: DM6LOQU)

Drug Name
Celecoxib
Synonyms
CEL; Celebra; Celebrex; Celecox; Celecoxi; Celocoxib; Eurocox; Medicoxib; Onsenal; Solexa; Xilebao; Celecoxib [Old RN]; Celecoxib [USAN]; Pfizer brand of celecoxib; SC 58635; SC58635; YM 177; YM177; AI-525; CEP-33222; Celebra (TN); Celebrex (TN); SC-58635; TPI-336; YM-177; Celebrex, Celebra, Celecoxib; Celecoxib (SC-58635); Celecoxib (JAN/USAN/INN); SC-58553, SC-58635; P-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide; Benzenesulfonamide,4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl); 4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide; 4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1Hpyrazol-1-yl] benzenesulfonamide; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide
Indication
Disease Entry ICD 11 Status REF
Dysmenorrhea GA34.3 Approved [1]
Lung cancer 2C25.0 Approved [1]
Osteoarthritis FA00-FA05 Approved [1]
Rheumatoid arthritis FA20 Approved [2]
Pain MG30-MG3Z Phase 3 [2]
Colon cancer 2B90.Z Investigative [1]
Familial adenomatous polyposis 2B90.Y Investigative [1]
Precancerous condition N.A. Investigative [1]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Analgesics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 381.4
Logarithm of the Partition Coefficient (xlogp) 3.4
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 7
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Elimination
2% of drug is excreted from urine in the unchanged form [3]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 17.48915 micromolar/kg/day [4]
Water Solubility
The ability of drug to dissolve in water is measured as 0.005 mg/mL [3]
Chemical Identifiers
Formula
C17H14F3N3O2S
IUPAC Name
4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide
Canonical SMILES
CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F
InChI
InChI=1S/C17H14F3N3O2S/c1-11-2-4-12(5-3-11)15-10-16(17(18,19)20)22-23(15)13-6-8-14(9-7-13)26(21,24)25/h2-10H,1H3,(H2,21,24,25)
InChIKey
RZEKVGVHFLEQIL-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
2662
ChEBI ID
CHEBI:41423
CAS Number
169590-42-5
DrugBank ID
DB00482
TTD ID
D03RTS
VARIDT ID
DR00520
INTEDE ID
DR0286
ACDINA ID
D00113
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Prostaglandin G/H synthase 2 (COX-2) TTVKILB PGH2_HUMAN Inhibitor [5]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [6]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [7]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [8]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [9]
Sulfotransferase 1A1 (SULT1A1) DEYWLRK ST1A1_HUMAN Substrate [10]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Dysmenorrhea
ICD Disease Classification GA34.3
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Prostaglandin G/H synthase 2 (COX-2) DTT PTGS2 2.03E-07 1.68 3.86
Sulfotransferase 1A1 (SULT1A1) DME SULT1A1 7.87E-07 -1.63E+00 -5.54E+00
Cytochrome P450 2C8 (CYP2C8) DME CYP2C8 1.51E-01 -1.41E-01 -8.46E-01
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 4.98E-01 1.97E-02 2.59E-01
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 3.04E-01 -5.14E-02 -1.57E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 3.90E-02 -3.45E-01 -1.49E+00
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Celecoxib
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Sulfasalazine DMICA9H Moderate Increased risk of nephrotoxicity by the combination of Celecoxib and Sulfasalazine. Rheumatoid arthritis [FA20] [11]
Dexamethasone DMMWZET Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Celecoxib and Dexamethasone. Rheumatoid arthritis [FA20] [12]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of Celecoxib and Leflunomide. Rheumatoid arthritis [FA20] [13]
Coadministration of a Drug Treating the Disease Different from Celecoxib (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Celecoxib and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [14]
Repaglinide DM5SXUV Moderate Increased risk of hypoglycemia by the combination of Celecoxib and Repaglinide. Acute diabete complication [5A2Y] [15]
Glibenclamide DM8JXPZ Moderate Increased risk of hypoglycemia by the combination of Celecoxib and Glibenclamide. Acute diabete complication [5A2Y] [15]
Tolazamide DMIHRNA Moderate Increased risk of hypoglycemia by the combination of Celecoxib and Tolazamide. Acute diabete complication [5A2Y] [15]
Nateglinide DMLK2QH Moderate Increased risk of hypoglycemia by the combination of Celecoxib and Nateglinide. Acute diabete complication [5A2Y] [15]
Glipizide DMZA5PQ Moderate Increased risk of hypoglycemia by the combination of Celecoxib and Glipizide. Acute diabete complication [5A2Y] [15]
Arn-509 DMT81LZ Moderate Increased metabolism of Celecoxib caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [16]
Oliceridine DM6MDCF Moderate Decreased metabolism of Celecoxib caused by Oliceridine mediated inhibition of CYP450 enzyme. Acute pain [MG31] [17]
Galantamine DMEO794 Moderate Decreased metabolism of Celecoxib caused by Galantamine mediated inhibition of CYP450 enzyme. Alzheimer disease [8A20] [18]
Donepezil DMIYG7Z Minor Decreased metabolism of Celecoxib caused by Donepezil mediated inhibition of CYP450 enzyme. Alzheimer disease [8A20] [19]
Metronidazole DMTIVEN Moderate Decreased metabolism of Celecoxib caused by Metronidazole mediated inhibition of CYP450 enzyme. Amoebiasis [1A36] [17]
Inotersen DMJ93CT Major Increased risk of nephrotoxicity by the combination of Celecoxib and Inotersen. Amyloidosis [5D00] [16]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Celecoxib and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [20]
Voriconazole DMAOL2S Moderate Decreased metabolism of Celecoxib caused by Voriconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [14]
Zafirlukast DMHNQOG Moderate Decreased metabolism of Celecoxib caused by Zafirlukast mediated inhibition of CYP450 enzyme. Asthma [CA23] [17]
Budesonide DMJIBAW Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Celecoxib and Budesonide. Asthma [CA23] [12]
Desipramine DMT2FDC Moderate Decreased metabolism of Celecoxib caused by Desipramine mediated inhibition of CYP450 enzyme. Attention deficit hyperactivity disorder [6A05] [17]
Ofloxacin DM0VQN3 Moderate Additive CNS depression effects by the combination of Celecoxib and Ofloxacin. Bacterial infection [1A00-1C4Z] [21]
Kanamycin DM2DMPO Moderate Increased risk of nephrotoxicity by the combination of Celecoxib and Kanamycin. Bacterial infection [1A00-1C4Z] [22]
Ciprofloxacin XR DM2NLS9 Moderate Additive CNS depression effects by the combination of Celecoxib and Ciprofloxacin XR. Bacterial infection [1A00-1C4Z] [21]
Trovafloxacin DM6AN32 Moderate Additive CNS depression effects by the combination of Celecoxib and Trovafloxacin. Bacterial infection [1A00-1C4Z] [21]
Sulfamethoxazole DMB08GE Moderate Decreased metabolism of Celecoxib caused by Sulfamethoxazole mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [17]
Sparfloxacin DMB4HCT Moderate Additive CNS depression effects by the combination of Celecoxib and Sparfloxacin. Bacterial infection [1A00-1C4Z] [21]
Streptomycin DME1LQN Moderate Increased risk of nephrotoxicity by the combination of Celecoxib and Streptomycin. Bacterial infection [1A00-1C4Z] [22]
Gemifloxacin DMHT34O Moderate Additive CNS depression effects by the combination of Celecoxib and Gemifloxacin. Bacterial infection [1A00-1C4Z] [21]
Norfloxacin DMIZ6W2 Moderate Additive CNS depression effects by the combination of Celecoxib and Norfloxacin. Bacterial infection [1A00-1C4Z] [21]
ABT-492 DMJFD2I Moderate Additive CNS depression effects by the combination of Celecoxib and ABT-492. Bacterial infection [1A00-1C4Z] [21]
Gentamicin DMKINJO Moderate Increased risk of nephrotoxicity by the combination of Celecoxib and Gentamicin. Bacterial infection [1A00-1C4Z] [22]
Netilmicin DMRD1QK Moderate Increased risk of nephrotoxicity by the combination of Celecoxib and Netilmicin. Bacterial infection [1A00-1C4Z] [22]
Levofloxacin DMS60RB Moderate Additive CNS depression effects by the combination of Celecoxib and Levofloxacin. Bacterial infection [1A00-1C4Z] [21]
Tobramycin DMUI0CH Moderate Increased risk of nephrotoxicity by the combination of Celecoxib and Tobramycin. Bacterial infection [1A00-1C4Z] [22]
Lomefloxacin DMVRH9C Moderate Additive CNS depression effects by the combination of Celecoxib and Lomefloxacin. Bacterial infection [1A00-1C4Z] [21]
Etidronic acid DM1XHYJ Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Celecoxib and Etidronic acid. Bone paget disease [FB85] [23]
Risedronate DM5FLTY Moderate Increased risk of nephrotoxicity by the combination of Celecoxib and Risedronate. Bone paget disease [FB85] [23]
Alendronate DMY2KX9 Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Celecoxib and Alendronate. Bone paget disease [FB85] [23]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Celecoxib and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [24]
Alpelisib DMEXMYK Moderate Increased metabolism of Celecoxib caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [25]
Tamoxifen DMLB0EZ Major Decreased metabolism of Celecoxib caused by Tamoxifen mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [26]
Iodipamide DMXIQYS Major Increased risk of nephrotoxicity by the combination of Celecoxib and Iodipamide. Cholelithiasis [DC11] [27]
Dihydrocodeine DMB0FWL Moderate Decreased metabolism of Celecoxib caused by Dihydrocodeine mediated inhibition of CYP450 enzyme. Chronic pain [MG30] [17]
Anisindione DM2C48U Moderate Increased plasma concentrations of Celecoxib and Anisindione due to competitive inhibition of the same metabolic pathway. Coagulation defect [3B10] [28]
Oxaliplatin DMQNWRD Moderate Decreased renal excretion of Celecoxib caused by Oxaliplatin mediated nephrotoxicity. Colorectal cancer [2B91] [29]
Drospirenone DM1A9W3 Moderate Increased risk of hyperkalemia by the combination of Celecoxib and Drospirenone. Contraceptive management [QA21] [30]
Methoxyflurane DML0RAE Moderate Increased risk of nephrotoxicity by the combination of Celecoxib and Methoxyflurane. Corneal disease [9A76-9A78] [16]
Dextromethorphan DMUDJZM Moderate Decreased metabolism of Celecoxib caused by Dextromethorphan mediated inhibition of CYP450 enzyme. Cough [MD12] [14]
Mifepristone DMGZQEF Moderate Decreased metabolism of Celecoxib caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [31]
Lumacaftor DMCLWDJ Moderate Increased metabolism of Celecoxib caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [32]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Celecoxib caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [33]
MK-8228 DMOB58Q Moderate Increased metabolism of Celecoxib caused by MK-8228 mediated induction of CYP450 enzyme. Cytomegaloviral disease [1D82] [34]
Aprepitant DM053KT Moderate Increased metabolism of Celecoxib caused by Aprepitant mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [35]
Sertraline DM0FB1J Moderate Decreased metabolism of Celecoxib caused by Sertraline mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [17]
Trimipramine DM1SC8M Moderate Decreased metabolism of Celecoxib caused by Trimipramine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [17]
Nortriptyline DM4KDYJ Moderate Decreased metabolism of Celecoxib caused by Nortriptyline mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [17]
Paroxetine DM5PVQE Moderate Decreased metabolism of Celecoxib caused by Paroxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [17]
OPC-34712 DMHG57U Major Decreased metabolism of Celecoxib caused by OPC-34712 mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [36]
Clomipramine DMINRKW Moderate Decreased metabolism of Celecoxib caused by Clomipramine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [17]
Trazodone DMK1GBJ Moderate Decreased metabolism of Celecoxib caused by Trazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [17]
Amoxapine DMKITQE Moderate Decreased metabolism of Celecoxib caused by Amoxapine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [17]
Doxepin DMPI98T Moderate Decreased metabolism of Celecoxib caused by Doxepin mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [17]
Maprotiline DMPWB7T Moderate Decreased metabolism of Celecoxib caused by Maprotiline mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [17]
Fenfluramine DM0762O Moderate Decreased metabolism of Celecoxib caused by Fenfluramine mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [17]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Celecoxib and Cannabidiol. Epileptic encephalopathy [8A62] [16]
Ethacrynic acid DM60QMR Moderate Antagonize the effect of Celecoxib when combined with Ethacrynic acid. Essential hypertension [BA00] [37]
Benzthiazide DMQWZ0H Moderate Antagonize the effect of Celecoxib when combined with Benzthiazide. Essential hypertension [BA00] [37]
Tolterodine DMSHPW8 Minor Decreased metabolism of Celecoxib caused by Tolterodine mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [38]
Darifenacin DMWXLYZ Moderate Decreased metabolism of Celecoxib caused by Darifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [39]
Miconazole DMPMYE8 Moderate Decreased metabolism of Celecoxib caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [17]
Cimetidine DMH61ZB Moderate Decreased metabolism of Celecoxib caused by Cimetidine mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [17]
Eplerenone DMF0NQR Moderate Increased risk of hyperkalemia by the combination of Celecoxib and Eplerenone. Heart failure [BD10-BD1Z] [40]
Carvedilol DMHTEAO Moderate Decreased metabolism of Celecoxib caused by Carvedilol mediated inhibition of CYP450 enzyme. Heart failure [BD10-BD1Z] [17]
Chlorothiazide DMLHESP Moderate Antagonize the effect of Celecoxib when combined with Chlorothiazide. Heart failure [BD10-BD1Z] [37]
Furosemide DMMQ8ZG Moderate Antagonize the effect of Celecoxib when combined with Furosemide. Heart failure [BD10-BD1Z] [37]
Amiloride DMRTSGP Moderate Antagonize the effect of Celecoxib when combined with Amiloride. Heart failure [BD10-BD1Z] [37]
Bumetanide DMRV7H0 Moderate Antagonize the effect of Celecoxib when combined with Bumetanide. Heart failure [BD10-BD1Z] [37]
Hydroflumethiazide DMVPUQI Moderate Antagonize the effect of Celecoxib when combined with Hydroflumethiazide. Heart failure [BD10-BD1Z] [37]
Isoniazid DM5JVS3 Moderate Decreased metabolism of Celecoxib caused by Isoniazid mediated inhibition of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [17]
Rifampin DMA8J1G Moderate Increased metabolism of Celecoxib caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [41]
Rifapentine DMCHV4I Moderate Increased metabolism of Celecoxib caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [42]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Celecoxib and Brentuximab vedotin. Hodgkin lymphoma [2B30] [43]
Delavirdine DM3NF5G Minor Decreased metabolism of Celecoxib caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [17]
Efavirenz DMC0GSJ Moderate Decreased metabolism of Celecoxib caused by Efavirenz mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [17]
Etravirine DMGV8QU Moderate Decreased metabolism of Celecoxib caused by Etravirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [44]
Gemfibrozil DMD8Q3J Moderate Decreased metabolism of Celecoxib caused by Gemfibrozil mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [17]
Fenofibrate DMFKXDY Moderate Decreased metabolism of Celecoxib caused by Fenofibrate mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [14]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Celecoxib and Mipomersen. Hyper-lipoproteinaemia [5C80] [45]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Celecoxib and Teriflunomide. Hyper-lipoproteinaemia [5C80] [13]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Celecoxib and BMS-201038. Hyper-lipoproteinaemia [5C80] [46]
Penbutolol DM4ES8F Moderate Decreased metabolism of Celecoxib caused by Penbutolol mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [17]
Nebivolol DM7F1PA Moderate Decreased metabolism of Celecoxib caused by Nebivolol mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [17]
Indapamide DMGN1PW Moderate Antagonize the effect of Celecoxib when combined with Indapamide. Hypertension [BA00-BA04] [37]
Trichlormethiazide DMHAQCO Moderate Antagonize the effect of Celecoxib when combined with Trichlormethiazide. Hypertension [BA00-BA04] [37]
Labetalol DMK8U72 Moderate Decreased metabolism of Celecoxib caused by Labetalol mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [17]
Hydrochlorothiazide DMUSZHD Moderate Antagonize the effect of Celecoxib when combined with Hydrochlorothiazide. Hypertension [BA00-BA04] [37]
Fludrocortisone DMUDIR8 Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Celecoxib and Fludrocortisone. Hypo-osmolality/hyponatraemia [5C72] [12]
Balsalazide DM7I1T9 Moderate Increased risk of nephrotoxicity by the combination of Celecoxib and Balsalazide. Indeterminate colitis [DD72] [11]
Propiomazine DMKY8V1 Moderate Decreased metabolism of Celecoxib caused by Propiomazine mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [17]
Methotrexate DM2TEOL Moderate Increased risk of hepatotoxicity by the combination of Celecoxib and Methotrexate. Leukaemia [2A60-2B33] [16]
Ibandronate DM0QZBN Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Celecoxib and Ibandronate. Low bone mass disorder [FB83] [16]
Porfimer Sodium DM7ZWNY Moderate Increased risk of photosensitivity reactions by the combination of Celecoxib and Porfimer Sodium. Lung cancer [2C25] [47]
PF-06463922 DMKM7EW Moderate Increased metabolism of Celecoxib caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [14]
Chloroquine DMSI5CB Moderate Decreased metabolism of Celecoxib caused by Chloroquine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [17]
Primaquine DMWQ16I Moderate Decreased metabolism of Celecoxib caused by Primaquine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [17]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Celecoxib and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [48]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Celecoxib and Idelalisib. Mature B-cell leukaemia [2A82] [49]
Clofarabine DMCVJ86 Moderate Increased risk of nephrotoxicity by the combination of Celecoxib and Clofarabine. Mature B-cell lymphoma [2A85] [16]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Celecoxib caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [16]
Propranolol DM79NTF Moderate Decreased metabolism of Celecoxib caused by Propranolol mediated inhibition of CYP450 enzyme. Migraine [8A80] [17]
Exjade DMHPRWG Major Increased risk of nephrotoxicity by the combination of Celecoxib and Exjade. Mineral absorption/transport disorder [5C64] [50]
Deflazacort DMV0RNS Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Celecoxib and Deflazacort. Muscular dystrophy [8C70] [12]
Methoxsalen DME8FZ9 Moderate Increased risk of photosensitivity reactions by the combination of Celecoxib and Methoxsalen. Mycosis fungoides [2B01] [14]
Imatinib DM7RJXL Moderate Decreased metabolism of Celecoxib caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [51]
Promethazine DM6I5GR Moderate Decreased metabolism of Celecoxib caused by Promethazine mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [17]
Ondansetron DMOTQ1I Moderate Decreased metabolism of Celecoxib caused by Ondansetron mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [17]
Dexfenfluramine DMJ7YDS Moderate Decreased metabolism of Celecoxib caused by Dexfenfluramine mediated inhibition of CYP450 enzyme. Obesity [5B80-5B81] [17]
Metolazone DMB39LO Moderate Antagonize the effect of Celecoxib when combined with Metolazone. Oedema [MG29] [37]
Polythiazide DMCH80F Moderate Antagonize the effect of Celecoxib when combined with Polythiazide. Oedema [MG29] [37]
Diclofenac DMPIHLS Moderate Increased risk of hepatotoxicity by the combination of Celecoxib and Diclofenac. Osteoarthritis [FA00-FA05] [52]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Celecoxib caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [53]
Pentazocine DM1XBHS Moderate Decreased metabolism of Celecoxib caused by Pentazocine mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [17]
Dextropropoxyphene DM23HCX Moderate Decreased metabolism of Celecoxib caused by Dextropropoxyphene mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [17]
Aspirin DM672AH Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Celecoxib and Aspirin. Pain [MG30-MG3Z] [54]
Methamphetamine DMPM4SK Moderate Decreased metabolism of Celecoxib caused by Methamphetamine mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [17]
Hydrocodone DMQ2JO5 Moderate Decreased metabolism of Celecoxib caused by Hydrocodone mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [17]
Oxycodone DMXLKHV Moderate Decreased metabolism of Celecoxib caused by Oxycodone mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [17]
Prednisone DM2HG4X Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Celecoxib and Prednisone. Postoperative inflammation [1A00-CA43] [12]
Hydrocortisone DMGEMB7 Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Celecoxib and Hydrocortisone. Postoperative inflammation [1A00-CA43] [12]
Enzalutamide DMGL19D Moderate Increased metabolism of Celecoxib caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [55]
Tamsulosin DM5QF9V Moderate Decreased metabolism of Celecoxib caused by Tamsulosin mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [56]
Levomepromazine DMIKFEL Moderate Decreased metabolism of Celecoxib caused by Levomepromazine mediated inhibition of CYP450 enzyme. Psychotic disorder [6A20-6A25] [17]
Fluphenazine DMIT8LX Moderate Decreased metabolism of Celecoxib caused by Fluphenazine mediated inhibition of CYP450 enzyme. Psychotic disorder [6A20-6A25] [17]
Triflupromazine DMKFQJP Moderate Decreased metabolism of Celecoxib caused by Triflupromazine mediated inhibition of CYP450 enzyme. Psychotic disorder [6A20-6A25] [17]
Bosentan DMIOGBU Moderate Increased metabolism of Celecoxib caused by Bosentan mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [57]
Everolimus DM8X2EH Major Increased risk of nephrotoxicity by the combination of Celecoxib and Everolimus. Renal cell carcinoma [2C90] [58]
Temsirolimus DMS104F Major Increased risk of nephrotoxicity by the combination of Celecoxib and Temsirolimus. Renal cell carcinoma [2C90] [58]
Gatifloxacin DMSL679 Moderate Additive CNS depression effects by the combination of Celecoxib and Gatifloxacin. Respiratory infection [CA07-CA4Z] [21]
Oxamniquine DM2QDX1 Moderate Decreased metabolism of Celecoxib caused by Oxamniquine mediated inhibition of CYP450 enzyme. Schistosomiasis [1F86] [17]
Mesoridazine DM2ZGAN Moderate Decreased metabolism of Celecoxib caused by Mesoridazine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [17]
Thioridazine DM35M8J Major Decreased metabolism of Celecoxib caused by Thioridazine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [59]
Aripiprazole DM3NUMH Moderate Decreased metabolism of Celecoxib caused by Aripiprazole mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [60]
Haloperidol DM96SE0 Moderate Decreased metabolism of Celecoxib caused by Haloperidol mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [17]
Perphenazine DMA4MRX Moderate Decreased metabolism of Celecoxib caused by Perphenazine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [17]
Trifluoperazine DMKBYWI Moderate Decreased metabolism of Celecoxib caused by Trifluoperazine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [17]
Risperidone DMN6DXL Moderate Decreased metabolism of Celecoxib caused by Risperidone mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [17]
Pimozide DMW83TP Major Decreased metabolism of Celecoxib caused by Pimozide mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [61]
Methylprednisolone DM4BDON Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Celecoxib and Methylprednisolone. Solid tumour/cancer [2A00-2F9Z] [12]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Celecoxib and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [16]
Prednisolone DMQ8FR2 Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Celecoxib and Prednisolone. Solid tumour/cancer [2A00-2F9Z] [12]
Pitolisant DM8RFNJ Moderate Decreased metabolism of Celecoxib caused by Pitolisant mediated inhibition of CYP450 enzyme. Somnolence [MG42] [16]
Disulfiram DMCL2OK Moderate Decreased metabolism of Celecoxib caused by Disulfiram mediated inhibition of CYP450 enzyme. Substance abuse [6C40] [17]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of Celecoxib and Naltrexone. Substance abuse [6C40] [62]
Warfarin DMJYCVW Moderate Increased plasma concentrations of Celecoxib and Warfarin due to competitive inhibition of the same metabolic pathway. Supraventricular tachyarrhythmia [BC81] [28]
Sirolimus DMGW1ID Major Increased risk of nephrotoxicity by the combination of Celecoxib and Sirolimus. Transplant rejection [NE84] [58]
Tacrolimus DMZ7XNQ Major Increased risk of nephrotoxicity by the combination of Celecoxib and Tacrolimus. Transplant rejection [NE84] [58]
Tolbutamide DM02AWV Moderate Increased risk of hypoglycemia by the combination of Celecoxib and Tolbutamide. Type 2 diabetes mellitus [5A11] [15]
Chlorpropamide DMPHZQE Moderate Increased risk of hypoglycemia by the combination of Celecoxib and Chlorpropamide. Type 2 diabetes mellitus [5A11] [15]
Olsalazine DMZW9HA Moderate Increased risk of nephrotoxicity by the combination of Celecoxib and Olsalazine. Ulcerative colitis [DD71] [11]
Cinoxacin DM4EWNS Moderate Additive CNS depression effects by the combination of Celecoxib and Cinoxacin. Urinary tract infection [GC08] [21]
Sulfamethizole DMGCHDS Moderate Decreased metabolism of Celecoxib caused by Sulfamethizole mediated inhibition of CYP450 enzyme. Urinary tract infection [GC08] [17]
Plazomicin DMKMBES Moderate Increased risk of nephrotoxicity by the combination of Celecoxib and Plazomicin. Urinary tract infection [GC08] [22]
Nalidixic acid DMRM0JV Moderate Additive CNS depression effects by the combination of Celecoxib and Nalidixic acid. Urinary tract infection [GC08] [21]
Triamcinolone DM98IXF Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Celecoxib and Triamcinolone. Vasomotor/allergic rhinitis [CA08] [12]
Methdilazine DMAUHQX Moderate Decreased metabolism of Celecoxib caused by Methdilazine mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [17]
Trimeprazine DMEMV9D Moderate Decreased metabolism of Celecoxib caused by Trimeprazine mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [17]
Propafenone DMPIBJK Moderate Decreased metabolism of Celecoxib caused by Propafenone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [17]
Flecainide DMSQDLE Moderate Decreased metabolism of Celecoxib caused by Flecainide mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [17]
Amiodarone DMUTEX3 Moderate Decreased metabolism of Celecoxib caused by Amiodarone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [17]
⏷ Show the Full List of 166 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
D&C red no. 28 E00491 6097185 Colorant
D&C red no. 33 E00261 19116 Colorant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Hydrazine yellow E00409 164825 Colorant
Isopropyl alcohol E00070 3776 Antimicrobial preservative; Solvent
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sodium stearyl fumarate E00545 23665634 lubricant
Ammonia E00007 222 Alkalizing agent
Butyl alcohol E00011 263 Flavoring agent; Solvent
Carmellose sodium E00625 Not Available Disintegrant
Crospovidone E00626 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
FD&C red no. 3 E00629 Not Available Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Gelatin E00630 Not Available Other agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Potassium hydroxide E00233 14797 Alkalizing agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium hydroxide E00234 14798 Alkalizing agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
⏷ Show the Full List of 29 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Celecoxib 50 mg capsule 50 mg Oral Capsule Oral
Celecoxib 400 mg capsule 400 mg Oral Capsule Oral
Celecoxib 100 mg capsule 100 mg Oral Capsule Oral
Celecoxib 200 mg capsule 200 mg Oral Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Celecoxib FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2892).
3 BDDCS applied to over 900 drugs
4 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
5 Pfizer. Product Development Pipeline. March 31 2009.
6 Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor. J Pharmacol Exp Ther. 2000 May;293(2):453-9.
7 Celecoxib is a substrate of CYP2D6: impact on celecoxib metabolism in individuals with CYP2C9*3 variants. Drug Metab Pharmacokinet. 2018 Oct;33(5):219-227.
8 Drug interactions in dentistry: the importance of knowing your CYPs. J Am Dent Assoc. 2004 Mar;135(3):298-311.
9 Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. Pharmacogenomics. 2009 Sep;10(9):1489-510.
10 Sulfonation of 17beta-estradiol and inhibition of sulfotransferase activity by polychlorobiphenylols and celecoxib in channel catfish, Ictalurus punctatus. Aquat Toxicol. 2007 Mar 10;81(3):286-92.
11 Novis BH, Korzets Z, Chen P, Bernheim J "Nephrotic syndrome after treatment with 5-aminosalicylic acid." Br Med J (Clin Res Ed) 296 (1988): 1442. [PMID: 3132281]
12 Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6. [PMID: 8724264]
13 EMEA "EMEA public statement on leflunomide (ARAVA) - severe and serious hepatic reactions.".
14 Cerner Multum, Inc. "Australian Product Information.".
15 Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
16 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
17 Product Information. Celebrex (celecoxib). Searle, Chicago, IL.
18 Product Information. Reminyl (galantamine) Janssen Pharmaceuticals, Titusville, NJ.
19 Product Information. Aricept (donepezil). Pfizer US Pharmaceuticals, New York, NY.
20 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
21 Product Information. Factive (gemifloxacin). GeneSoft Inc, San Francisco, CA.
22 Assael BM, Chiabrando C, Gagliardi L, Noseda A, Bamonte F, Salmona M "Prostaglandins and aminoglycoside nephrotoxicity." Toxicol Appl Pharmacol 78 (1985): 386-94. [PMID: 4049389]
23 Product Information. Actonel (risedronate). Procter and Gamble Pharmaceuticals, Cincinnati, OH.
24 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
25 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
26 Amchin J, Ereshefsky L, Zarycranski W, Taylor K, Albano D, Klockowski PM "Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe." J Clin Pharmacol 41 (2001): 443-51. [PMID: 11304901]
27 Wong GT, Lee EY, Irwin MG. Contrast induced nephropathy in vascular surgery.?Br J Anaesth. 2016;117 Suppl 2:ii63-ii73. [PMID: 27566809]
28 Haase KK, Roias-Fernandez CH "Potential interaction between celecoxib and warfarin." Ann Pharmacother 34 (2000): 666-7. [PMID: 10852097]
29 Product Information. Eloxatin (oxaliplatin). Sanofi Winthrop Pharmaceuticals, New York, NY.
30 Product Information. Yasmin (drospirenone-ethinyl estradiol) Berlex Laboratories, Richmond, CA.
31 Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
32 Cerner Multum, Inc. "Canadian Product Information.".
33 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
34 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
35 Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
36 Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
37 Muller FO, Schall R, Devaal AC, Groenewoud G, Hundt HKL, Middle MV "Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers." Eur J Clin Pharmacol 48 (1995): 247-51. [PMID: 7589049]
38 Brynne N, Svanstrom C, AbergWistedt A, Hallen B, Bertilsson L "Fluoxetine inhibits the metabolism of tolterodin-pharmacokinetic implications and proposed clinical relevance." Br J Clin Pharmacol 48 (1999): 553-63. [PMID: 10583026]
39 Product Information. Enablex (darifenacin). Novartis Pharmaceuticals, East Hanover, NJ.
40 Abdel-Haq B, Magagna A, Favilla S, Salvetti A "Hemodynamic and humoral interactions between perindopril and indomethacin in essential hypertensive subjects." J Cardiovasc Pharmacol 18 (1991): s33-6. [PMID: 1725198]
41 Jayasagar G, Krishna Kumar M, Chandrasekhar K, Madhusudan Rao Y "Influence of rifampicin pretreatment on the pharmacokinetics of celecoxib in healthy male volunteers." Drug Metabol Drug Interact 19 (2003): 287-95. [PMID: 14768975]
42 Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
43 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
44 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
45 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
46 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
47 Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
48 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
49 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
50 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
51 Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
52 Product Information. Solaraze (diclofenac topical). Doak Dermatologics Division, Fairfield, NJ.
53 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
54 Abdel-Rahman MS, Reddi AS, Curro FA, Turkall RM, Kadry AM, Hansrote JA "Bioavailability of aspirin and salicylamide following oral co-administration in human volunteers." Can J Physiol Pharmacol 69 (1991): 1436-42. [PMID: 1777842]
55 Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
56 Franco-Salinas G, de la Rosette JJ, Michel MC "Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations." Clin Pharmacokinet 49 (2010): 177-88. [PMID: 20170206]
57 Product Information. Tracleer (bosentan). Acetelion Pharmaceuticals US, Inc, South San Francisco, CA.
58 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
59 Abernethy DR, Greenblatt DJ, Steel K, Shader RI "Impairment of hepatic drug oxidation by propoxyphene." Ann Intern Med 97 (1982): 223-4. [PMID: 7103282]
60 Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
61 Canadian Pharmacists Association.
62 Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.